Clinical Characteristics of Relapsed Patients
| . | TEL/AML1 . | Not Tested . | Total . | |
|---|---|---|---|---|
| Negative . | Positive . | |||
| Initial protocol | ||||
| 81-01 | 11 | 0 | 38 | 49 |
| 85-01 | 7 | 0 | 15 | 22 |
| 87-01 | 9 | 0 | 24 | 33 |
| 91-01 | 4 | 1 | 16 | 21 |
| Risk category4-150 | ||||
| Standard | 4 | 0 | 30 | 34 |
| High | 25 | 1 | 51 | 77 |
| Very High | 2 | 0 | 12 | 14 |
| Age at Dx | ||||
| <1 yr | 2 | 0 | 3 | 5 |
| 1.01-9.9 yr | 18 | 1 | 68 | 87 |
| >10 yr | 11 | 0 | 22 | 33 |
| Immunophenotype | ||||
| B-cell | 30 | 1 | 84 | 115 |
| T-cell | 1 | 0 | 6 | 7 |
| Unknown | 0 | 0 | 3 | 3 |
| t(9;22) | ||||
| Yes | 3 | 0 | 8 | 11 |
| No | 26 | 1 | 65 | 92 |
| Unknown | 2 | 0 | 20 | 22 |
| WBC | ||||
| <50K/μL | 25 | 1 | 67 | 93 |
| 50K/μL ≤ 100K/μL | 0 | 0 | 7 | 7 |
| ≥100K/μL | 6 | 0 | 19 | 25 |
| CNS leukemia | ||||
| Yes | 3 | 0 | 4 | 7 |
| No | 27 | 1 | 89 | 117 |
| Unknown | 1 | 0 | 0 | 1 |
| Sex | ||||
| Male | 22 | 1 | 52 | 75 |
| Female | 9 | 0 | 41 | 50 |
| Duration of 1st CR4-151 | ||||
| <18 mo | 4 | 0 | 29 | 33 |
| 18-30 mo | 6 | 1 | 26 | 33 |
| >30 mo | 21 | 0 | 38 | 59 |
| Median (month) | 37.8 | 22.3 | 26.9 | 29 |
| . | TEL/AML1 . | Not Tested . | Total . | |
|---|---|---|---|---|
| Negative . | Positive . | |||
| Initial protocol | ||||
| 81-01 | 11 | 0 | 38 | 49 |
| 85-01 | 7 | 0 | 15 | 22 |
| 87-01 | 9 | 0 | 24 | 33 |
| 91-01 | 4 | 1 | 16 | 21 |
| Risk category4-150 | ||||
| Standard | 4 | 0 | 30 | 34 |
| High | 25 | 1 | 51 | 77 |
| Very High | 2 | 0 | 12 | 14 |
| Age at Dx | ||||
| <1 yr | 2 | 0 | 3 | 5 |
| 1.01-9.9 yr | 18 | 1 | 68 | 87 |
| >10 yr | 11 | 0 | 22 | 33 |
| Immunophenotype | ||||
| B-cell | 30 | 1 | 84 | 115 |
| T-cell | 1 | 0 | 6 | 7 |
| Unknown | 0 | 0 | 3 | 3 |
| t(9;22) | ||||
| Yes | 3 | 0 | 8 | 11 |
| No | 26 | 1 | 65 | 92 |
| Unknown | 2 | 0 | 20 | 22 |
| WBC | ||||
| <50K/μL | 25 | 1 | 67 | 93 |
| 50K/μL ≤ 100K/μL | 0 | 0 | 7 | 7 |
| ≥100K/μL | 6 | 0 | 19 | 25 |
| CNS leukemia | ||||
| Yes | 3 | 0 | 4 | 7 |
| No | 27 | 1 | 89 | 117 |
| Unknown | 1 | 0 | 0 | 1 |
| Sex | ||||
| Male | 22 | 1 | 52 | 75 |
| Female | 9 | 0 | 41 | 50 |
| Duration of 1st CR4-151 | ||||
| <18 mo | 4 | 0 | 29 | 33 |
| 18-30 mo | 6 | 1 | 26 | 33 |
| >30 mo | 21 | 0 | 38 | 59 |
| Median (month) | 37.8 | 22.3 | 26.9 | 29 |
Clinical characteristics of patients studied.
Abbreviations: Dx, Diagnosis; WBC, white blood cell count; CNS, central nervous system; CR, clinical remission.
Among tested and not tested (P = .04).
There was a longer duration of first remission in the tested group that was statistically significant (P = .01). Note that the median of 37.8 months reflects the patients who were tested, excluding the TEL/AML1-positive patient. The median duration of first remission of all patients tested, including theTEL/AML1-positive patient, is 35.6 months.